| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w28755 |
| 来源ID | Working Paper 28755 |
| Which Markets (Don't) Drive Pharmaceutical Innovation? Evidence From U.S. Medicaid Expansions | |
| Craig Garthwaite; Rebecca Sachs; Ariel Dora Stern | |
| 发表日期 | 2021-05-10 |
| 出版年 | 2021 |
| 语种 | 英语 |
| 摘要 | Pharmaceutical innovation policy involves managing a tradeoff between high prices for new products in the short-term and stronger incentives to develop products for the future. Prior research has documented a causal relationship between market size and pharmaceutical research and development (R&D) activities. The existing literature, however, provides no evidence of how this relationship varies across markets. We investigate whether recent expansions in state Medicaid programs caused an increase in R&D. We find no evidence of a response, potentially a result of Medicaid’s low reimbursement for pharmaceuticals, suggesting low(er) price markets may have different dynamics with respect to innovation policy. |
| 主题 | Public Economics ; Health, Education, and Welfare ; Health ; Industrial Organization ; Antitrust ; Regulatory Economics ; Development and Growth ; Innovation and R& ; D |
| URL | https://www.nber.org/papers/w28755 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/586429 |
| 推荐引用方式 GB/T 7714 | Craig Garthwaite,Rebecca Sachs,Ariel Dora Stern. Which Markets (Don't) Drive Pharmaceutical Innovation? Evidence From U.S. Medicaid Expansions. 2021. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w28755.pdf（1056KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
